INSM
Insmed Incorporated
A maker of inhaled medicines for rare lung diseases, Insmed sells ARIKAYCE for a stubborn bacterial lung infection and BRINSUPRI for bronchiectasis, with gene therapies for muscular dystrophy and ALS in the works. Founded in 1988 in Richmond, Virginia, it began by developing insulin-like growth factor proteins before turning to respiratory care. Its ARIKAYCE was the first drug approved under the FDA's Limited Population Pathway, designed for serious infections in small patient groups.
CUSIP: 457669307HealthcareUS2 holders
Total Value
$277.87M
Total Shares
2.61M
Net Share Change
+2.31M
Activity
2 buying
Investor
Value
Shares
Weight
Change
